Triptorelin GnRHCheck methods and identity
How triptorelin was tested for sustained testosterone suppression
2 numbered sourcesSource years 2009, 2026
Peptides are short amino-acid chains joined by peptide bonds. Some trigger hormone release when they first meet a receptor and change that response during continued exposure. Triptorelin is a synthetic ten-amino-acid mimic of gonadotropin-releasing hormone, or GnRH. Sustained exposure reduces pituitary signaling to the testes and lowers testosterone. U.S. prescribing information lists advanced prostate cancer as the approved indication for Trelstar, a triptorelin pamoate product. An older, directly relevant phase III study tested how often a long-acting formulation brought testosterone below a prespecified threshold and kept it there. [1, 2]
The hormone response has two phases. Early stimulation can temporarily increase pituitary hormone output and testosterone. As the pituitary becomes less responsive to sustained stimulation, output falls and the testes receive less signal to make testosterone. The prescribing information describes an initial rise and the possibility that it can temporarily worsen some cancer symptoms. A testosterone value obtained early and one obtained after suppression develops therefore describe different parts of the response. [1]
The 2009 trial enrolled 120 patients with advanced prostate cancer in South Africa. Researchers knew what treatment patients received, and everyone entered the same study group. Approximately 98 percent reached the trial's low-testosterone threshold at the first main assessment, and about 93 percent maintained suppression over the specified follow-up. The trial provides a direct estimate of biochemical suppression in this group over the period the researchers observed. [2]
Testosterone is a meaningful treatment measure because some prostate cancers depend on androgen signaling. Still, a threshold reached in a blood test and a difference in how a patient feels or how long the cancer stays controlled are distinct outcomes. Without a comparison group, the study cannot establish how the formulation performs against another drug on progression, symptoms, or survival. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 2.Lundström EA et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clinical Drug Investigation (publication 2009). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
